The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Litvinenko I.V.

Kafedra nervnykh bolezneĭ i kafedra psikhiatrii Voenno-meditsinskoĭ akademii

Dynin P.S.

S.M. Kirov Saint-Petersburg Military Medical Academy, St-Petersburg, Russia

Trufanov A.G.

Kafedry nervnykh bolezneĭ i rentgenologii i radiologii Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Gimadutdinov R.F.

S.M. Kirov Saint-Petersburg Military Medical Academy, St-Petersburg, Russia

Maltsev D.S.

S.M. Kirov Saint-Petersburg Military Medical Academy, St-Petersburg, Russia

Eye as an object of investigation of cognitive impairment in Parkinson’s disease

Authors:

Litvinenko I.V., Dynin P.S., Trufanov A.G., Gimadutdinov R.F., Maltsev D.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2): 105‑114

DOI: 10.17116/jnevro2018118062105

Read: 954 times

Download PDF (RU)
Contact the author
Table of contents

EYE AS AN OBJECT OF INVESTIGATION OF COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE
EYE AS AN OBJECT OF INVESTIGATION OF COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE

To cite this article:

Litvinenko IV, Dynin PS, Trufanov AG, Gimadutdinov RF, Maltsev DS. Eye as an object of investigation of cognitive impairment in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2):105‑114. (In Russ.)
https://doi.org/10.17116/jnevro2018118062105

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Cyto­megalovirus chorioretinitis in human immu­nodeficiency virus (case study). Russian Annals of Ophthalmology. 2025;(1):62-68
The role of the stru­cture of the lamina cribrosa in the diagnosis and treatment of glaucoma. Stru­ctural and circulatory changes in the lamina cribrosa with aging and elevated intraocular pressure. Russian Annals of Ophthalmology. 2025;(1):76-82
Choroidal neovascularization asso­ciated with choroidal nevi. Russian Annals of Ophthalmology. 2025;(1):104-112
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
The effect of bila­teral subthalamic nucleus deep brain stimulation on gait and bala­nce in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):94-101
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Abstract:

Objective. To study visual and spatial disorders in Parkinson's disease (PD). Material and methods. One hundred and eighteen patients with PD and 30 healthy people (the control group) were studied. All participants underwent neurological and ophthalmological examinations. PD progression was assessed using The Hoehn and Yahr scale. MMSE, FAB and other psychological tests were administered. Optical coherence tomography (OCT) and MRI of the brain were performed. Results and Conclusion. The relationship of the variation in the thickness of various parts of the retina and brain cortex with cognitive deficit that manifests itself as visual-spatial disturbances is shown. The complex diagnostic technique, including neuropsychological and instrumental method (OCT of the retina, MRI of the brain with MRI-morphometry), should be used.

Keywords:

cognitive impairment
Parkinson's disease
visual-spatial disorders
cognitive deficit
optical coherence tomography
ganglionic layer
retinal nerve fiber layer
MR-morphometry

Authors:

Litvinenko I.V.

Kafedra nervnykh bolezneĭ i kafedra psikhiatrii Voenno-meditsinskoĭ akademii

Dynin P.S.

S.M. Kirov Saint-Petersburg Military Medical Academy, St-Petersburg, Russia

Trufanov A.G.

Kafedry nervnykh bolezneĭ i rentgenologii i radiologii Voenno-meditsinskoĭ akademii, Sankt-Peterburg

Gimadutdinov R.F.

S.M. Kirov Saint-Petersburg Military Medical Academy, St-Petersburg, Russia

Maltsev D.S.

S.M. Kirov Saint-Petersburg Military Medical Academy, St-Petersburg, Russia

Close metadata

References:

  1. Levin OS, Fedorova NV. Bolezn’ Parkinsona. 2-e izd. M.: MEDpress-inform; 2012. (In Russ.)
  2. Litvan I, Kieburtz K, Tröster AI, Aarsland D. Strengths and challenges in conducting clinical trials in Parkinson’s disease mild cognitive impairment. Mov Disord. 2018;33:520-527. https://doi.org/10.1002/mds.27345
  3. Dawson BK, Fereshtehnejad S, Anang JBM, Nomura T, Rios-Romenets S, Nakashima K, Gagnon JF, Postuma RB. Office-Based Screening for Dementia in Parkinson Disease. The Montreal Parkinson Risk of Dementia Scale in 4 Longitudinal Cohorts. JAMA Neurol. 2018;75(6):704-710. https://doi.org/10.1001/jamaneurol.2018.0254
  4. Orrù G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neuroscience & Biobehavioral Reviews. 2012;36(4):1140-1152. https://doi.org/10.1016/j.neubiorev.2012.01.004
  5. Weintraub D, Tröster AI, Marras C, Stebbins G. Initial cognitive changes in Parkinson’s disease. Mov Disord. 2018;33:511-519. https://doi.org/10.1002/mds.27330
  6. Chesnokova N.B., Pavlenko T.A., Ugrumov M.V. Ophthalmic disorders as a manifestation of Parkinson’’s disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;117(9):124-131 (In Russ.)
  7. Armstrong RA. Oculo-Visual Dysfunction in Parkinson’s Disease. Journal of Parkinson’s Disease. 2015;5(4):715-726. https://doi.org/10.3233/JPD-150686
  8. Hill E, Stuart S, Lord S, Din SD, Rochester L. Vision, Visuo-Cognition and Postural Control in Parkinson’s Disease: An Associative Pilot Study. Gait & Posture. 2016;48:74-76. https://doi.org/10.1016/j.gaitpost.2016.04.024
  9. Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson’s disease. Brain. 2016;139(11):2827-2843. https://doi.org/10.1093/brain/aww175
  10. Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s Disease. Movement Disorders. 2014;29(1):61-67. https://doi.org/10.1002/mds.25543
  11. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Movement disorders. 2011;26(13):2387-2395. https://doi.org/10.1002/mds.23891
  12. Polo V, Satue M, Rodrigo MJ, Mallada SZO, Alejos MRA, Rubio MPB, Lázaro MI, Poves JML, Júlvez LP, Martín EG. Visual dysfunction and its correlation with retinal changes in patients with Parkinson’s disease: an observational cross-sectional study. BMJ Open. 2016;6(5):e009658. https://doi.org/10.1136/bmjopen-2015-009658
  13. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11:697-707. https://doi.org/10.1016/S1474-4422(12)70152-7
  14. Frederick JM, Rayborn ME, Laties AM. Lam DM, Hollyfield JG. Dopaminergic neurons in the human retina. Comp. Neurol. 1982;210(1):65-79. https://doi.org/10.1002/cne.902100108
  15. Maximova E.M. Neurotransmitter Interaction of Retinal neurons and Retinal Remodeling after Degeneration of Photoreceptors. Sensornye systemy. 2008;22(1):36-51 (In Russ.)
  16. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S. Detection of retinal changes in Parkinson’s disease with spectral-domain optical coherence tomography. Clin Ophthalmol. 2010;4:1427-1432. https://doi.org/10.1186/1471-2415-12-54
  17. Garcia-Martin E, Pablo LE, Bambo MP, Alarcia R, Polo V, Larrosa JM, Vilades E, Cameo B, Orduna E, Ramirez T, Satue M. Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson’s disease. PLoS ONE. 2017;12(5):e0177163. https://doi.org/10.1371/journal.pone.0177163
  18. Kromer R, Buhmann C, Hidding U, Keserü M, Keserü D, Hassenstein A, Stemplewitz B. Evaluation of Retinal Vessel Morphology in Patients with Parkinson’s Disease Using Optical Coherence Tomography. PLoS ONE. 2016;11(8):e0161136. https://doi.org/10.1371/journal.pone.0161136
  19. Satue M, Obis J, Rodrigo MJ, Otin S, Fuertes MI, Vilades E, Gracia H, Ara JR, Alarcia R, Polo V, Larrosa JM, Pablo LE, Garcia-Martin E. Optical Coherence Tomography as a Biomarker for Diagnosis, Progression, and Prognosis of Neurodegenerative Diseases. Journal of Ophthalmology. 2016; 2016:8503859. https://doi.org/10.1155/2016/8503859
  20. Bogdanov R.R., Manannikova E.I., Abramenko A.S., Maratkanova T.V., Kotov S.V. Morphometric parameters of the neurodegenerative process in Parkinson’s disease and chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(10):40-44 (In Russ.)
  21. Emelin AYu, Odinak MM, Lobzin VYu, Vorobyev SV, Kiselev VN. Current capacities for neuroimaging in the differential diagnosis of cognitive impairments. Nevrologia, Neiropsychiatria, Psychosomatica. 2012;4(2S):51-55. (In Russ.) https://doi.org/10.14412/2074-2711-2012-2509.
  22. Lobzin VYu, Kiselev VN, Fokin VF, Emelin AYu, Vorobyev SV, Lupanov IA, Sokolov AV, Efimtsev AYu. Voxel-based moprhometry in Alzheimer’s disease and vascular cognitive impairment. Vestnik Rossiiskoi Voenno-medicinskoi academii. 2013;3(43):48-54 (In Russ.)
  23. Weil RS, Schwarzkopf DS, Bahrami B, Fleming SM, Jackson BM, Goch TJC, Saygin AP, Miller LE, Pappa K, Pavisic I, Schade RN, Noyce AJ, Crutch SJ, O’Keeffe AG, Schrag AE, Morris HR. Assessing cognitive dysfunction in Parkinson’s disease: An online tool to detect visuo‐perceptual deficits. Mov Disord. 2018;33:544-553. https://doi.org/10.1002/mds.27311
  24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
  25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. https://doi.org/10.1212/WNL.17.5.427
  26. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: Frontal Assessment Battery at bedside. Neurology. 2000;55:621-1626. https://doi.org/10.1212/WNL.57.3.565
  27. Emre M, Arsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders. 2007;15(22):1689-1707. https://doi.org/10.1002/mds.21507
  28. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinican. Journal of psychiatric research. 1975;12:189-198. https://doi.org/10.1016/0022-3956(75)90026-6
  29. Luria A.R. Vyshie korkovye funstii cheloveka i ikh narusheniya pri local’nykh porazheniyakh mozga. M.: MGU; 1969. (In Russ.)
  30. Wasserman L.I. Metody neiropsychologicheskoy diagnostiki. SPb.: Stroylespechat’; (In Russ.)
  31. Rybalsky M.I. Illusii i hallucinacii. Baku: Maarif; 1983 (In Russ.)
  32. Uchiyama M, Nishio Y, Yokoi K, Hosokai Y, Takeda A, Mori E. Pareidolia in Parkinson’s disease without dementia: a positron emission tomography study. Parkinsonism Relat Disord. 2015;21:603-609. https://doi.org/10.1016/j.parkreldis.2015.03.020
  33. Kaur M, Saxena R, Singh D, Behari M, Sharma P, Menon V. Correlation between structural and functional retinal changes in Parkinson disease. J of Neuro-Ophthalmol. 2015;35(3):254-258. https://doi.org/10.1097/WNO.0000000000000240
  34. Sari S, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. J Neuroophthalmol. 2015;35(2):117-121. https://doi.org/10.1097/WNO.0000000000000203
  35. Boyko EV, Koskin SA, Kharitonova NN, Shishkin MM. Metodika obsledovania bol’nogo v oftalmologicheskoy klinike. SPb; VMedA; 2013 (In Russ.)
  36. Garcia-Martin E, Satue M, Fuertes I, Otin S, Alarcia R, Herrero R, Bambo MP, Fernandez J, Pablo LE.Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson’s disease. Ophthalmol. 2012;119(10):2161-2167. https://doi.org/10.1016/j.ophtha.2012.05.003
  37. Mailankody P, Battu R, Khanna A, Lenka A, Yadav R, Pal PK. Optical coherence tomography as a tool to evaluate retinal changes in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(10):1164-1169. https://doi.org/10.1016/j.parkreldis.2015.08.002
  38. Chorostecki J, Seraji-Bozorgzad N, Shah AJ. Characterization of retinal architecture in Parkinson’s disease. Neurol Sci. 2015;355(1-2):44-48. https://doi.org/10.1016/j.jns.2015.05.007
  39. Kirbas S. Retinal nerve fiber layer thickness in Parkinson disease. J of Neuro-Ophthalmol. 2013;33(1):62-65. https://doi.org/10.1097/WNO.0b013e3182701745
  40. Morgia CA, Barboni P, Rizzo G. et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? Eur J of Neurology. 2013;20(1):198-201. https://doi.org/10.1111/j.1468-1331.2012.03701.x.
  41. Litvinenko I.V., Odinak M.M. Correction of motor complications of Parkinson’s disease by agonist of D3 receptors Mirapex. Nevrologicheskiy zhurnal. 2002;7(5):36-39. (In Russ.)
  42. Nodel’ M.R., Yachno N.N. Nervous and mental disorders of Parkinson›s disease. Nevrologia, Neiropsychiatria, Psychosomatica. 2009;1(2):3-8. (In Russ.)
  43. Anderson P. Visual Test May Flag Risk for Parkinson’s Dementia. Medscape. 2017. https://www.medscape.com/viewarticle/881860?src=soc_fb_share
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.